HC Wainwright reaffirmed their neutral rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright also issued estimates for Aadi Bioscience’s Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at ($0.73) […]
Related Keywords
Aadi Bioscience , Neil Desai , Decheng Capital , Securities Exchange Commission , Td Asset Management Inc , Marquette Asset Management , Aadi Bioscience Inc , Free Report , Get Free Report , Chairman Neil Desai , Exchange Commission , Asset Management , Management Inc , Aadi Bioscience Daily , Nasdaq Aadi , Maadi , Medical , Reiterated Rating , Hc Wainwright ,
vimarsana.com © 2020. All Rights Reserved.